Mortality and recurrence patterns of breast cancer patients diagnosed under a screening programme versus comparable non-screened breast cancer patients from the same population: Analytical survey from 2002 to 2012

A. García Fernández, C. Chabrera, M. García Font, M. Fraile, J. M. Lain, S. Gónzalez, C. Corral, M. Torras, J. Torres, M. Teixido, I. Barco, R. López, C. Gónzalez, A. Pessarrodona, N. Giménez

Research output: Contribution to journalReview articleResearchpeer-review

11 Citations (Scopus)

Abstract

Breast cancer screening programmes seem to bring about significant benefits, including decreased mortality, although they may also have some drawbacks such as false-negative and false-positive results. This study aims to compare the clinical outcome of a group of patients undergoing a breast cancer screening programme with that of a synchronous non-screened group of patients matched for age and follow-up period. We studied basic characteristics of epidemiology, immunohistochemistry, loco-regional relapse, distant metastases, disease-free interval and overall and specific mortality. We compared 510 patients in the screened group with 394 non-screened patients, along the period of 2002-2012. Screening was applied on a target population of 49,847 and was based on double-projection, double-read mammograms. Two years were allowed per round. Overall participation for the five rounds considered was 75.2 %, with 86.5 % coverage, and a total cumulative population of 123,445. The non-participant women amounted 40,794. Tumour detection rate for the screened women was 3.8 per thousand (475/123,445), while the corresponding rate for non-participants was 9.4 per thousand (382/40,797). Incidence of luminal A subtype was 15 % higher in screened than that in non-screened patients (95 % confidence interval (CI) 8-22 %). Conversely, the triple-negative subtype was 6 % higher in the non-screened group (95 % CI 2-10 %). Incidence of breast conservative treatments and sentinel node biopsies was significantly higher in the screened group. Overall mortality was 2.6 times higher in non-screened than that in screened group (95 % CI 1.2-5.6) After 10 years of experience with our own screening programme, we believe that included patients receive a benefit versus comparable non-screened breast cancer patients, with acceptable benefit-risk relation. © 2013 International Society of Oncology and BioMarkers (ISOBM).
Original languageEnglish
Pages (from-to)1945-1953
JournalTumor Biology
Volume35
Issue number3
DOIs
Publication statusPublished - 1 Jan 2014

Keywords

  • Breast neoplasms
  • Mass screening
  • Mortality

Fingerprint Dive into the research topics of 'Mortality and recurrence patterns of breast cancer patients diagnosed under a screening programme versus comparable non-screened breast cancer patients from the same population: Analytical survey from 2002 to 2012'. Together they form a unique fingerprint.

Cite this